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Introduction
Benign hereditary chorea is a rare disorder characterized by childhood-
onset, non-progressive chorea, with or without associated respiratory and
thyroid dysfunction.1 It is referred to as ‘‘brain-lung-thyroid’’ syndrome
when all three systems are involved.2 It is caused by autosomal dominant
mutations in the NKX2-1 gene (previously TITF-1), on chromosome 14.3
It is a genetically heterogeneous condition, with over 30 different causa-
tive mutations identified.4
Other neurological manifestations of benign hereditary chorea and
NKX2-1-related disorders include dystonia, myoclonus, tics, tremor,
dysarthria, ataxia, hypotonia, and motor developmental delay. Neuro-
psychiatric symptoms such as attention deficit hyperactivity disorder
(ADHD), have also been reported.1,5
Pharmacologic treatment of chorea and other abnormal move-
ments in NKX2-1-related disorders has been disappointing. It typically
involves levodopa or tetrabenazine; however, side effects are often
limiting.5 We report and illustrate the case of a young female patient
with brain-lung-thyroid syndrome and an immediate improvement of
her involuntary movements with methylphenidate (Video 1).
Methods
We obtained written informed consent from the subject and legal
representative under a study approved by the ethics committee of
the Montreal Children’s Hospital. We performed a retrospective chart
review and assessed the patient before and after methylphenidate
hydrochloride ingestion.
Results
The patient was born at term following an uncomplicated preg-
nancy. She suffered from transient respiratory distress. She was first
referred to the neurology department at 2 years of age for hypotonia
and motor delay. Thyroid function tests were performed at age 2 as
part of the investigations for hypotonia and revealed hypothyroidism.
The patient also had asthma. Chorea was noted on examination,
predominantly in the limbs, with superimposed generalized dystonia
and occasional myoclonic jerks. The cranial muscles were relatively
spared. The patient was found to carry a de novo heterozygous missense
mutation in NKX2-1 (NM_001079668, hg19). This variant (c.626G.C,
p.Arg209Pro) has not been reported in any online database
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(ESP, 1000g, ExAC, gnomAD). It affects a highly conserved amino
acid and is located in a highly conserved region involved in DNA
binding.6 dbNSFP databases provided by Annovar predict the variant
to be pathogenic. It has been published as pathogenic in three indivi-
duals from one family with childhood-onset hypothyroidism and
movement disorders.6
Psychostimulant medication was initiated at the age of 5 for a con-
comitant diagnosis of ADHD. The patient experienced a sudden and
dramatic improvement of her gait and stopped using her walker. She
is now 10 years old and was initially treated with methylphenidate
(up to 20 mg daily), and later with controlled-release methylphenidate
hydrochloride (up to 30 mg daily). The medication adjustments were
made based on her ADHD symptoms and treatment impact on her
appetite. She has been on the same regimen since age 8 and has not
required any additional treatment for her abnormal movements. She
exhibits significant reduction of her choreic movements and dystonic
postures within 30 minutes after receiving her daily dose, with con-
sequent improvement in her gait, speech, and fine motor skills. These
benefits consistently last throughout the day. The patient and her
parents report that the involuntary movements only become more
bothersome in the evening and peak in the morning prior to methyl-
phenidate ingestion. This is consistent with the reported duration
of action (8 to 12 hours) of extended-release forms of stimulant
medications.7
Discussion
The central nervous system stimulant methylphenidate is typically
not considered as a treatment option for chorea or other movement
disorders. However, it was previously associated with incidental
improvement in two patients with benign hereditary chorea.8,9 In
1996, Friederich first reported subjective improvements of handwriting
and gait in a young male patient treated with methylphenidate.8
He hypothesized that this response was the result of a reduction in
stress exacerbating the chorea rather than a direct effect. The dramatic,
immediate response in our patient argues against this hypothesis.
Questions remain about the role of dopamine in benign hereditary
chorea. NKX2-1 is believed to be involved in the embryologic striatum
development.10,11 Immunohistochemical studies on an affected post-
mortem brain revealed loss of striatal interneurons and efferent fibers.11
In addition, a recent dopaminergic neuronal imaging study found
decreased dopamine receptor binding.12
Tetrabenazine is a dopamine-depleting agent that inhibits the
vesicular monoamine transporter 2, whereas levodopa is a dopamine
precursor converted to dopamine by striatal enzymes. Both have
shown suboptimal results in the treatment of movement disorders in
patients with benign hereditary chorea and NKX2-1-related disorders.5
Methylphenidate is a dopamine reuptake blocker that facilitates dopa-
minergic transmission. Although dopamine appears to be involved in
the pathogenesis of NKX2-1-related disorders, the benefit of methyl-
phenidate over levodopa and other dopaminergic medications remains
unexplained.
This case illustrates for the first time an immediate and objective
response to methylphenidate in a patient with brain-lung-thyroid
syndrome. Further research is warranted to better document and
explain this response. Our report supports a trial of methylphenidate
to improve functional abilities in patients affected by NKX2-1-related
disorders, especially given its more favorable side effect profile com-
pared to other pharmacologic agents.
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